Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Quoin Pharmaceuticals Ltd.QNRX · Entity 7876 | Chief Financial Officer | December 23, 2024 | December 27, 2024 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Quoin Pharmaceuticals Ltd.
Report date December 23, 2024 · Filed December 27, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Ordinary SharesSEC Table I · non-derivative | Direct | 151,077 |
Reported balance
After 2024-12-23 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2024-12-23 · Purchase · Acquired 122,221 · Balance 151,077 F1: Reported securities are represented by American Depositary Shares ("ADSs"). Each ADS represents one ordinary share of the Issuer. F2: Each ADS purchased together with a Series F Warrant to purchase one ADS and a Series G Warrant to purchase one ADS in the Issuer's public offering which closed on December 23, 2024, at a combined public offering price of $0.45. The Series F Warrants and the Series G Warrants are collectively referred to as the "Warrants." |
| Series F Warrants (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.45 · Expires 2026-12-23 | Direct | 122,221 |
Reported balance
After 2024-12-23 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2024-12-23 · Purchase · Acquired 122,221 · Balance 122,221 F2: Each ADS purchased together with a Series F Warrant to purchase one ADS and a Series G Warrant to purchase one ADS in the Issuer's public offering which closed on December 23, 2024, at a combined public offering price of $0.45. The Series F Warrants and the Series G Warrants are collectively referred to as the "Warrants." F3: The Warrants were exercisable immediately, subject to a beneficial ownership cap. |
| Series G Warrants (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.45 · Expires 2029-12-24 | Direct | 122,221 |
Reported balance
After 2024-12-23 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2024-12-23 · Purchase · Acquired 122,221 · Balance 122,221 F2: Each ADS purchased together with a Series F Warrant to purchase one ADS and a Series G Warrant to purchase one ADS in the Issuer's public offering which closed on December 23, 2024, at a combined public offering price of $0.45. The Series F Warrants and the Series G Warrants are collectively referred to as the "Warrants." F3: The Warrants were exercisable immediately, subject to a beneficial ownership cap. |
Filing footnotes · ownership attribution and instrument terms
F1: Reported securities are represented by American Depositary Shares ("ADSs"). Each ADS represents one ordinary share of the Issuer.
F2: Each ADS purchased together with a Series F Warrant to purchase one ADS and a Series G Warrant to purchase one ADS in the Issuer's public offering which closed on December 23, 2024, at a combined public offering price of $0.45. The Series F Warrants and the Series G Warrants are collectively referred to as the "Warrants."
F3: The Warrants were exercisable immediately, subject to a beneficial ownership cap.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| December 23, 2024 Filed Dec 27, 2024 22:16 UTC | Quoin Pharmaceuticals Ltd. QNRX · Entity 7876 | PurchaseSeries G Warrants (right to buy) · Derivative | 122,221 | Not disclosed Strike: $0.45 | Not disclosed |
DisclosureSEC source: 0001104659-24-132187 · tm2431988-2_4seq1.xml · derivative · entry 3 Dunn Gordon · CIK 0001958139 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 122,221 Underlying: ADS · 122,221 shares Expires 2029-12-24 F2 · kind: Each ADS purchased together with a Series F Warrant to purchase one ADS and a Series G Warrant to purchase one ADS in the Issuer's public offering which closed on December 23, 2024, at a combined public offering price of $0.45. The Series F Warrants and the Series G Warrants are collectively referred to as the "Warrants." F2 · price: Each ADS purchased together with a Series F Warrant to purchase one ADS and a Series G Warrant to purchase one ADS in the Issuer's public offering which closed on December 23, 2024, at a combined public offering price of $0.45. The Series F Warrants and the Series G Warrants are collectively referred to as the "Warrants." F3 · derivative.exercise_date: The Warrants were exercisable immediately, subject to a beneficial ownership cap. Read SEC document |
| December 23, 2024 Filed Dec 27, 2024 22:16 UTC | Quoin Pharmaceuticals Ltd. QNRX · Entity 7876 | PurchaseSeries F Warrants (right to buy) · Derivative | 122,221 | Not disclosed Strike: $0.45 | Not disclosed |
DisclosureSEC source: 0001104659-24-132187 · tm2431988-2_4seq1.xml · derivative · entry 2 Dunn Gordon · CIK 0001958139 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 122,221 Underlying: ADS · 122,221 shares Expires 2026-12-23 F2 · kind: Each ADS purchased together with a Series F Warrant to purchase one ADS and a Series G Warrant to purchase one ADS in the Issuer's public offering which closed on December 23, 2024, at a combined public offering price of $0.45. The Series F Warrants and the Series G Warrants are collectively referred to as the "Warrants." F2 · price: Each ADS purchased together with a Series F Warrant to purchase one ADS and a Series G Warrant to purchase one ADS in the Issuer's public offering which closed on December 23, 2024, at a combined public offering price of $0.45. The Series F Warrants and the Series G Warrants are collectively referred to as the "Warrants." F3 · derivative.exercise_date: The Warrants were exercisable immediately, subject to a beneficial ownership cap. Read SEC document |
| December 23, 2024 Filed Dec 27, 2024 22:16 UTC | Quoin Pharmaceuticals Ltd. QNRX · Entity 7876 | PurchaseOrdinary Shares | 122,221 | $0.45 | $54,999.45 |
DisclosureSEC source: 0001104659-24-132187 · tm2431988-2_4seq1.xml · nonDerivative · entry 1 Dunn Gordon · CIK 0001958139 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 151,077 F1 · security: Reported securities are represented by American Depositary Shares ("ADSs"). Each ADS represents one ordinary share of the Issuer. F2 · kind: Each ADS purchased together with a Series F Warrant to purchase one ADS and a Series G Warrant to purchase one ADS in the Issuer's public offering which closed on December 23, 2024, at a combined public offering price of $0.45. The Series F Warrants and the Series G Warrants are collectively referred to as the "Warrants." Read SEC document |
| December 09, 2024 Filed Dec 10, 2024 21:51 UTC | Quoin Pharmaceuticals Ltd. QNRX · Entity 7876 | GrantShare Option (Right to Buy) · Derivative | 338,994 | $0.00 Strike: $0.78 | $0.00 |
DisclosureSEC source: 0001104659-24-127243 · tm2430519-7_4seq1.xml · derivative · entry 1 Dunn Gordon · CIK 0001958139 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 338,994 Underlying: ADS · 338,994 shares Expires 2034-12-09 F1 · derivative.exercise_price: The number of securities underlying the option and the exercise price are listed in terms of American Depositary Shares ("ADSs"). Each ADS represents one ordinary share of the Issuer. F1 · shares: The number of securities underlying the option and the exercise price are listed in terms of American Depositary Shares ("ADSs"). Each ADS represents one ordinary share of the Issuer. F2 · derivative.exercise_date: The option vests in four annual installments with 20% vesting on each of December 9, 2025, 2026 and 2027 and 40% vesting on December 9, 2028. F1 · derivative.underlying: The number of securities underlying the option and the exercise price are listed in terms of American Depositary Shares ("ADSs"). Each ADS represents one ordinary share of the Issuer. F1 · derivative.underlying_shares: The number of securities underlying the option and the exercise price are listed in terms of American Depositary Shares ("ADSs"). Each ADS represents one ordinary share of the Issuer. F1 · balance_after: The number of securities underlying the option and the exercise price are listed in terms of American Depositary Shares ("ADSs"). Each ADS represents one ordinary share of the Issuer. Read SEC document |
| September 10, 2024 Filed Sep 11, 2024 20:30 UTC | Quoin Pharmaceuticals Ltd. QNRX · Entity 7876 | PurchaseOrdinary Shares | 10,000 | $0.71 | $7,100.00 |
DisclosureSEC source: 0001104659-24-098940 · tm2423807-1_4seq1.xml · nonDerivative · entry 5 Dunn Gordon · CIK 0001958139 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 28,856 F1 · shares: Reported securities are represented by American Depositary Shares ("ADSs"). Each ADS represents one ordinary shares of the Issuer. Read SEC document |
| September 10, 2024 Filed Sep 11, 2024 20:30 UTC | Quoin Pharmaceuticals Ltd. QNRX · Entity 7876 | PurchaseOrdinary Shares | 10,000 | $0.91 | $9,100.00 |
DisclosureSEC source: 0001104659-24-098940 · tm2423807-1_4seq1.xml · nonDerivative · entry 4 Dunn Gordon · CIK 0001958139 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 18,856 F1 · shares: Reported securities are represented by American Depositary Shares ("ADSs"). Each ADS represents one ordinary shares of the Issuer. Read SEC document |
| September 09, 2024 Filed Sep 11, 2024 20:30 UTC | Quoin Pharmaceuticals Ltd. QNRX · Entity 7876 | PurchaseOrdinary Shares | 4,000 | $0.80 | $3,200.00 |
DisclosureSEC source: 0001104659-24-098940 · tm2423807-1_4seq1.xml · nonDerivative · entry 3 Dunn Gordon · CIK 0001958139 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,856 F1 · shares: Reported securities are represented by American Depositary Shares ("ADSs"). Each ADS represents one ordinary shares of the Issuer. Read SEC document |
| September 09, 2024 Filed Sep 11, 2024 20:30 UTC | Quoin Pharmaceuticals Ltd. QNRX · Entity 7876 | PurchaseOrdinary Shares | 4,000 | $0.78 | $3,120.00 |
DisclosureSEC source: 0001104659-24-098940 · tm2423807-1_4seq1.xml · nonDerivative · entry 2 Dunn Gordon · CIK 0001958139 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,856 F1 · shares: Reported securities are represented by American Depositary Shares ("ADSs"). Each ADS represents one ordinary shares of the Issuer. Read SEC document |
| September 09, 2024 Filed Sep 11, 2024 20:30 UTC | Quoin Pharmaceuticals Ltd. QNRX · Entity 7876 | PurchaseOrdinary Shares | 856 | $0.80 | $684.80 |
DisclosureSEC source: 0001104659-24-098940 · tm2423807-1_4seq1.xml · nonDerivative · entry 1 Dunn Gordon · CIK 0001958139 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 856 F1 · shares: Reported securities are represented by American Depositary Shares ("ADSs"). Each ADS represents one ordinary shares of the Issuer. Read SEC document |
| October 26, 2023 Filed Oct 30, 2023 20:12 UTC | Quoin Pharmaceuticals Ltd. QNRX · Entity 7876 | GrantShare Option (Right to Buy) · Derivative | 51,149 | $0.00 Strike: $5.75 | $0.00 |
DisclosureSEC source: 0001104659-23-112570 · tm2329341-4_4seq1.xml · derivative · entry 1 Dunn Gordon · CIK 0001958139 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 51,149 Underlying: American Depositary Share · 51,149 shares Expires 2033-10-26 F1 · derivative.exercise_price: The number of securities underlying the option and the exercise price are listed in terms of American Depositary Shares ("ADSs"), with sixty thousand (60,000) ordinary shares of the Issuer represented by one (1) ADS. F1 · shares: The number of securities underlying the option and the exercise price are listed in terms of American Depositary Shares ("ADSs"), with sixty thousand (60,000) ordinary shares of the Issuer represented by one (1) ADS. F2 · derivative.exercise_date: The option vests in four annual installments with 20% vesting on each of October 26, 2024, 2025 and 2026 and 40% vesting on October 26, 2027. F1 · derivative.underlying: The number of securities underlying the option and the exercise price are listed in terms of American Depositary Shares ("ADSs"), with sixty thousand (60,000) ordinary shares of the Issuer represented by one (1) ADS. F1 · derivative.underlying_shares: The number of securities underlying the option and the exercise price are listed in terms of American Depositary Shares ("ADSs"), with sixty thousand (60,000) ordinary shares of the Issuer represented by one (1) ADS. F1 · balance_after: The number of securities underlying the option and the exercise price are listed in terms of American Depositary Shares ("ADSs"), with sixty thousand (60,000) ordinary shares of the Issuer represented by one (1) ADS. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.